Citations

Clear

3030 citation(s) found for "Susan, M".

B-Cell NHL Subtype Risk Associated with Autoimmune Conditions and PRS
Wang, Sophia , Vajdic, Claire M. , Linet, Martha S. , Slager, Susan L. , Nieters, Alexandra, Casabonne, Delphine , Cerhan, James R. , Cozen, Wendy , Brown, Elizabeth E. , Bracci, Paige M. , Turner, Jennifer , Hjalgrim, Henrik , Bhatti, Parveen , Flowers, Christopher R. , Paltiel, Ora , Holly, Elizabeth A., Weisenburger, Dennis D. , Cocco, Pierluigi , Breen, Elizabeth C. , Lan, Qing , Roos, Anneclaire J. De , Smith, Martyn T. , Kricker, Anne , Zheng, Tongzhang, Skibola, Christine F., Clavel, Jacqueline , Monnereau, Alain, Rothman, Nathaniel , Benavente, Yolanda , Hartge, Patricia, Smedby, Karin E. , Monnereau, Alain , Wang, Sophia S , Cerhan, James R , Cozen, Wendy , Martínez-Maza, Otoniel , Turner, Jennifer , Hjalgrim, Henrik , Bhatti, Parveen , Birmann, Brenda M , Kane, Eleanor , Weisenburger, Dennis D , Maynadié, Marc , Cocco, Pierluigi , Breen, Elizabeth Crabb , Lan, Qing , Brooks-Wilson, Angela R , Roman, Eve , Boffetta, Paolo , Kricker, Anne , Clavel, Jacqueline , Vajdic, Claire M , De Roos, Anneclaire J , Slager, Susan L , Voutsinas, Jenna M. , Alarcón, Graciela S. , Martı́nez-Maza, Otoniel , Zhang, Yawei , Birmann, Brenda M. , Kane, Eleanor , Foretová, Lenka , Brooks‐Wilson, Angela , Roman, Eve , Chanock, Stephen Jacob , Rothman, Nathaniel

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | May 4, 2022 | Volume: 31 | Issue: 5 | Pages: 1103-1110

10.1158/1055-9965.epi-21-0875 | PMID 35244686 Get It

Abstract Background: A previous International Lymphoma Epidemiology (InterLymph) Consortium evaluation of joint associations between five immune gene variants and autoimmune conditions reported interactions between B-cell response-mediated autoimmune conditions and the rs1800629 genotype on risk of B-cell non–Hodgkin lymphoma (NHL) subtypes. Here, we extend that evaluation using NHL subtype-specific polygenic risk scores (PRS) constructed from loci identified in genome-wide association studies of three common B-cell NHL subtypes. Methods: In a pooled analysis of NHL cases and controls of Caucasian descent from 14 participating InterLymph studies, we evaluated joint associations between B-cell–mediated autoimmune conditions and tertile (T) of PRS for risk of diffuse large B-cell lymphoma (DLBCL; n = 1,914), follicular lymphoma (n = 1,733), and marginal zone lymphoma (MZL; n = 407), using unconditional logistic regression. Results: We demonstrated a positive association of DLBCL PRS with DLBCL risk [T2 vs. T1: OR = 1.24; 95% confidence interval (CI), 1.08–1.43; T3 vs. T1: OR = 1.81; 95% CI, 1.59–2.07; P-trend (Ptrend) < 0.0001]. DLBCL risk also increased with increasing PRS tertile among those with an autoimmune condition, being highest for those with a B-cell–mediated autoimmune condition and a T3 PRS [OR = 6.46 vs. no autoimmune condition and a T1 PRS, Ptrend < 0.0001, P-interaction (Pinteraction) = 0.49]. Follicular lymphoma and MZL risk demonstrated no evidence of joint associations or significant Pinteraction. Conclusions: Our results suggest that PRS constructed from currently known subtype-specific loci may not necessarily capture biological pathways shared with autoimmune conditions. Impact: Targeted genetic (PRS) screening among population subsets with autoimmune conditions may offer opportunities for identifying those at highest risk for (and early detection from) DLBCL.
Abstract 9544: Physical Activity in Individuals With Hypertrophic Cardiomyopathy: Baseline Data From the Prospective "Lifestyle and Exercise in Hcm" (live-hcm) Study
Lampert, Rachel , Ackerman, Michael J. , Marino, Bradley S. , Burg, Matthew M. , Ainsworth, Barbara E. , Balaji, Seshadri , Czosek, Richard J. , Bos, Martijn, Choudhury, Lubna , Etheridge, Susan P. , Ware, James S, Maron, Martin S. , Eidem, Benjamin W., Saarel, Elizabeth V. , Maron, Barry J. , Cannom, David S. , Briske, Kaylie A., Simone, Laura, Barth, Cheryl , Concannon, Maryann, Day, Sharlene M. , Salberg, Lisa , Tome, Maite , Ho, Carolyn Y. , James, Cynthia A. , Emery, Michael S. , Cooper, Robert , Geske, Jeffrey B. , Lal, Ashwin K. , Ware, James S. , Dubin, Anne M. , Gray, Belinda , Molossi, Silvana M , Saberi, Sara , Jacoby, Daniel Louis , Harmon, Kimberly G. , Hall, Kevin D. , Olshansky, Brian , Link, Mark S. , Law, Ian H. , Estes, N.A. Mark , Li, Fangyong

Mayo Clinic

Circulation | April 28, 2022 | Volume: 144 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.144.suppl_1.9544 Get It

Introduction: Safety of vigorous exercise for individuals with appropriately-treated HCM remains debated. Physical activity practices in this population have not been described. The objective of this report is to describe physical activity pattern in HCM patients. Long term follow up which is ongoing will determine safety of vigorous exercise. Methods: The NIH-funded LIVE-HCM study prospectively enrolled individuals age 8-60 years with clinically overt HCM or patients with a positive genetic test for sarcomeric HCM. Participants (or parents, for children) answered surveys describing activity patterns. Vigorous exercise was defined as > 6 METS for > 60 hours per year. Clinical and demographic data were derived from medical record review. Results: Among 1798 participants, 745 (41%) reported exercising vigorously, including 296 competitive athletes, with 59 at high-school or college varsity level, 770 (43%) were exercising at moderate, and 283 (16%) at low levels. Of those working, 6% described jobs more active than walking, including 16 in protective services, and 11 in sports/coaching. Clinical/demographic data including imaging characteristics and treatments, are shown in Table, and were mostly similar amongst the exercise-groups. Conclusions: Many patients with HCM are engaged in vigorous exercise including competitive athletics. Prospective follow-up of this cohort is ongoing. Comparison of arrhythmic outcomes outcomes in vigorous exercisers vs moderate/low level exercisers will help determine the safety of exercise in HCM patients.
Bilateral Oophorectomy and the Risk of Breast Cancer in BRCA1 Mutation Carriers: A Reappraisal
Menkiszak, Janusz , McCuaig, Jeanna , Metcalfe, Kelly , Foulkes, William D. , Sun, Sophie , Karlan, Beth Y. , Eisen, Andrea , Olopade, Olufunmilayo I. , Senter, Leigha , Bordeleau, Louise , Sun, Ping , Narod, Steven A. , Kim, Raymond H. , Menkiszak, Janusz , Foulkes, William D , Karlan, Beth Y , Olopade, Olufunmilayo I , Couch, Fergus J. , Huzarski, Tomasz , Senter, Leigha , Singer, Christian F , Eng, Charis , Fruscio, Robert , Narod, Steven A , Metcalfe, Kelly A , Eisen, Andrea , Bordeleau, Louise , Kim, Raymond H , Kotsopoulos, Joanne , Lubiński, Jan , Gronwald, Jacek , Neuhausen, Susan L. , Tung, Nadine , Couch, Fergus J. , Huzarski, Tomasz , Singer, Christian F. , Eng, Charis , Fruscio, Robert , Pal, Tuya

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | April 27, 2022 | Volume: 31 | Issue: 7 | Pages: 1351-1358

10.1158/1055-9965.epi-21-1196 | PMID 35477169 Get It

Abstract Background: The lack of consensus on whether bilateral oophorectomy impacts risk of developing breast cancer among BRCA1 mutation carriers might be attributed to various biases, specifically, cancer-induced testing bias due to inclusion of prevalent cases. We conducted two complementary matched case–control analyses to evaluate the association of oophorectomy and BRCA1 breast cancer. Methods: A research questionnaire was administered every two years to collect information on exposures and disease. In the first analysis, we limited the study to prevalent breast cancer cases (diagnosed prior to study entry; n = 2,962) who were matched to controls on year of birth and country of residence (n = 4,358). In the second approach, we limited to 330 incident cases (diagnosed in the follow-up period) and 1,548 matched controls. Conditional logistic regression was used to estimate the adjusted odds ratios (OR) and 95% confidence intervals (CI) of invasive breast cancer. Results: In the first approach, there was a significant inverse association between oophorectomy and the risk of developing breast cancer [OR = 0.43; 95% confidence interval (CI), 0.34–0.55; P < 00001]. In the second approach, there was no association between oophorectomy and risk (OR = 1.21; 95% CI, 0.87–1.70; P = 0.26). Conclusions: The inclusion of women with a personal history of breast cancer prior to ascertainment likely impacts upon the association of oophorectomy and BRCA1 breast cancer risk. Impact: Oophorectomy is unlikely a determinant of breast cancer risk in BRCA1 mutation carriers but should be offered at age 35 to reduce the risk of ovarian and fallopian tube cancer.
Controversies in Acute Stroke Treatment
Brethour, Mary, Nyström, Karin , Broughton, Sandra S., Kiernan, Terri E, Perez, Amy, Handler, Diane, Swatzell, Victoria, Yang, Joanna Jiehong, Starr, Michele, Seagraves, Karen B., Cudlip, Fern, Biby, Sharon , Tocco, Susan, Owens, Pauline, Alexandrov, Anne W. , Broughton, Sandra, Kiernan, Terri-Ellen J.

Mayo Clinic

AACN Advanced Critical Care | April 25, 2022 | Volume: 23 | Issue: 2 | Pages: 158-172

10.4037/nci.0b013e31824fe1b6 Get It

The evidence base supporting the management of patients with acute stroke is evolving at a rapid rate, as new methods that aim to reduce disability and death from stroke are explored. Intravenous tissue plasminogen activator remains the only treatment shown in numerous studies to reduce disability 3 months after stroke with no increase in the risk of death and a relatively minor rate of symptomatic intracerebral hemorrhage complications. Despite these findings, health care providers have been slow to adopt this evidence-based treatment, which results in many patients experiencing disability caused by stroke. Numerous controversies exist related to the management of patients with acute stroke, including the use of tissue plasminogen activator, positioning and early mobility, blood pressure lowering in acute intracerebral hemorrhage, and even the use of innovative advanced practice nurse–led stroke treatment teams, with varying amounts of evidence available to provide direction. This article explores controversies associated with both approved and evolving treatments for ischemic and hemorrhagic stroke and makes recommendations for practice on the basis of the body of existing evidence, with an aim to improve the delivery of acute stroke treatment.
Social Support, Social Isolation, and Burnout: Cross-Sectional Study of U.S. Residents Exploring Associations With Individual, Interpersonal, Program, and Work-Related Factors
West, Colin P. , Rackley, Sandra , Dozois, Eric J. , Moeschler, Susan M. , Stelling, Brianna E. Vaa , Satele, Daniel , Leep Hunderfund, Andrea N, Rackley, Sandra J, Vaa Stelling, Brianna E, Winters, Richard C. , Satele, Daniel V, Dyrbye, Liselotte N. , West, C P , Hunderfund, Andrea N. Leep

Mayo Clinic

Academic Medicine | April 20, 2022 | Volume: 97 | Issue: 8 | Pages: 1184-1194

10.1097/acm.0000000000004709 | PMID 35442910 Get It

Abstract Purpose To examine associations of social support and social isolation with burnout, program satisfaction, and organization satisfaction among a large population of U.S. residents and fellows and to identify correlates of social support and social isolation. Method All residents and fellows enrolled in graduate medical education programs at Mayo Clinic sites were surveyed in February 2019. Survey items measured social support (emotional and tangible), social isolation, burnout, program satisfaction, and organization satisfaction. Factors of potential relevance to social support were collected (via the survey, institutional administrative records, and interviews with program coordinators and/or program directors) and categorized as individual, interpersonal, program, or work-related factors (duty hours, call burden, elective time, vacation days used before survey administration, required away rotations, etc.). Multivariable regression analyses were conducted to examine relationships between variables. Results Of 1,146 residents surveyed, 762 (66%) from 58 programs responded. In adjusted models, higher emotional and tangible support were associated with lower odds of burnout and higher odds of program and organization satisfaction, while higher social isolation scores were associated with higher odds of burnout and lower odds of program satisfaction and organization satisfaction. Independent predictors of social support and/or social isolation included age, gender, relationship status, parental status, postgraduate year, site, ratings of the program leadership team, ratings of faculty relationships and faculty professional behaviors, satisfaction with autonomy, and vacation days used before survey administration. Conclusions This study demonstrates that social support and social isolation are strongly related to burnout and satisfaction among residents and fellows. Personal and professional relationships, satisfaction with autonomy, and vacation days are independently associated with social support and/or social isolation, whereas most program and work-related factors are not. Additional studies are needed to determine if social support interventions targeting these factors can improve well-being and enhance satisfaction with training.
Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial
Shanafelt, Tait D. , Wang, Victoria , Hanson, Curtis A. , Paietta, Elisabeth , O’Brien, Susan , Jelinek, Diane F., Braggio, Esteban , Leis, José F., Zhang, Cong Christine, Cashen, Amanda F. , Mato, Anthony R. , Singh, Avina K., Mullane, Michael P., Little, Richard F. , Stone, Richard M. , Litzow, Mark R. , Tallman, Martin S. , Braggio, Esteban , Barr, Paul M , Little, Richard F , Erba, Harry Paul , Litzow, Mark R. , Kay, Neil E , Shanafelt, Tait D , Barrientos, Jacqueline C. , Coutré, Steven , Barr, Paul M. , Kay, Neil E.

Mayo Clinic

Blood | April 15, 2022 | Volume: 140 | Issue: 2 | Pages: 112-120

10.1182/blood.2021014960 | PMID 35427411 Get It

Abstract Herein, we present the long-term follow-up of the randomized E1912 trial comparing the long-term efficacy of ibrutinib–rituximab (IR) therapy to fludarabine, cyclophosphamide, and rituximab (FCR) and describe the tolerability of continuous ibrutinib. The E1912 trial enrolled 529 treatment-naïve patients aged ≤70 years with chronic lymphocytic leukemia (CLL). Patients were randomly assigned (2:1 ratio) to receive IR or 6 cycles of FCR. With a median follow-up of 5.8 years, median progression-free survival (PFS) is superior for IR (hazard ratio [HR], 0.37; P < .001). IR improved PFS relative to FCR in patients with both immunoglobulin heavy chain variable region (IGHV) gene mutated CLL (HR: 0.27; P < .001) and IGHV unmutated CLL (HR: 0.27; P < .001). Among the 354 patients randomized to IR, 214 (60.5%) currently remain on ibrutinib. Among the 138 IR-treated patients who discontinued treatment, 37 (10.5% of patients who started IR) discontinued therapy due to disease progression or death, 77 (21.9% of patients who started IR) discontinued therapy for adverse events (AEs)/complications, and 24 (6.8% of patients who started IR) withdrew for other reasons. Progression was uncommon among patients able to remain on ibrutinib. The median time from ibrutinib discontinuation to disease progression or death among those who discontinued treatment for a reason other than progression was 25 months. Sustained improvement in overall survival (OS) was observed for patients in the IR arm (HR, 0.47; P = .018). In conclusion, IR therapy offers superior PFS relative to FCR in patients with IGHV mutated or unmutated CLL, as well as superior OS. Continuous ibrutinib therapy is tolerated beyond 5 years in the majority of CLL patients. This trial was registered at www.clinicaltrials.gov as #NCT02048813.
Complications and outcomes of posterior fossa decompression with duraplasty versus without duraplasty for pediatric patients with Chiari malformation type I and syringomyelia: a study from the Park-Reeves Syringomyelia Research Consortium
Akbari, S. Hassan A. , Ackerman, Laurie L. , Adelson, P. David , Albert, Gregory W. , Aldana, Philipp R. , Alden, Tord D. , Anderson, Richard C. E. , Bauer, David F. , Bethel-Anderson, Tammy, Bierbrauer, Karin S. , Brockmeyer, Douglas L. , Chern, Joshua J. , Couture, Daniel E., Durham, Susan, Ellenbogen, Richard G. , Eskandari, Ramin , Fuchs, Herbert E., Greene, Stephanie , Gross, Naina L. , Guillaume, Daniel, Hankinson, Todd C. , Heuer, Gregory G. , Iantosca, Mark, Iskandar, Bermans J. , Jackson, Eric M. , Kaufman, Bruce A., Keating, Robert F., Khan, Nicklaus R., Krieger, Mark D., Leonard, Jeffrey R. , Maher, Cormac O. , Mangano, Francesco T. , McComb, J. Gordon , McEvoy, Sean D., Meehan, Thanda, Muhlbauer, Michael S., O’Neill, Brent R., Olavarria, Greg, Ragheb, John , Shannon, Chevis N. , Stone, Scellig , Strahle, Jennifer M. , Tamber, Mandeep S. , Torner, James C., Tuite, Gerald F. , Tyler‐Kabara, Elizabeth C. , Wait, Scott D. , Wellons, John C. , Whitehead, William E. , Limbrick, David D. , Torner, James C. , Yahanda, Alexander T. , Ahmed, Raheel , Daniels, David J. , Dlouhy, Brian J , Grant, Gerald A. , Graupman, Patrick C. , Greenfield, Jeffrey P. , Guillaume, Daniel J., Jallo, George I. , Johnston, James M. , Menezes, Arnold H. , Selden, Nathan R. W. , Shah, Manish N. , Shimony, Joshua S. , Park, Tae Sung , Limbrick, David D.

Mayo Clinic

Journal of Neurosurgery: Pediatrics | April 15, 2022 | Volume: 30 | Issue: 1 | Pages: 39-51

10.3171/2022.2.peds21446 | PMID 35426814 Get It

OBJECTIVE The aim of this study was to determine differences in complications and outcomes between posterior fossa decompression with duraplasty (PFDD) and without duraplasty (PFD) for the treatment of pediatric Chiari malformation type I (CM1) and syringomyelia (SM). METHODS The authors used retrospective and prospective components of the Park-Reeves Syringomyelia Research Consortium database to identify pediatric patients with CM1-SM who received PFD or PFDD and had at least 1 year of follow-up data. Preoperative, treatment, and postoperative characteristics were recorded and compared between groups. RESULTS A total of 692 patients met the inclusion criteria for this database study. PFD was performed in 117 (16.9%) and PFDD in 575 (83.1%) patients. The mean age at surgery was 9.86 years, and the mean follow-up time was 2.73 years. There were no significant differences in presenting signs or symptoms between groups, although the preoperative syrinx size was smaller in the PFD group. The PFD group had a shorter mean operating room time (p < 0.0001), fewer patients with > 50 mL of blood loss (p = 0.04), and shorter hospital stays (p = 0.0001). There were 4 intraoperative complications, all within the PFDD group (0.7%, p > 0.99). Patients undergoing PFDD had a 6-month complication rate of 24.3%, compared with 13.7% in the PFD group (p = 0.01). There were no differences between groups for postoperative complications beyond 6 months (p = 0.33). PFD patients were more likely to require revision surgery (17.9% vs 8.3%, p = 0.002). PFDD was associated with greater improvements in headaches (89.6% vs 80.8%, p = 0.04) and back pain (86.5% vs 59.1%, p = 0.01). There were no differences between groups for improvement in neurological examination findings. PFDD was associated with greater reduction in anteroposterior syrinx size (43.7% vs 26.9%, p = 0.0001) and syrinx length (18.9% vs 5.6%, p = 0.04) compared with PFD. CONCLUSIONS PFD was associated with reduced operative time and blood loss, shorter hospital stays, and fewer postoperative complications within 6 months. However, PFDD was associated with better symptom improvement and reduction in syrinx size and lower rates of revision decompression. The two surgeries have low intraoperative complication rates and comparable complication rates beyond 6 months.
Cardiac Magnetic Resonance at 3.0 T in Patients With C282Y Homozygous Hereditary Hemochromatosis
Byrne, Danielle, Walsh, John P., Murphy, Ross T., McMorrow, Jason, Fagan, Andrew J., Poetrzyk, Aneta Kecler, Durand, Michael E., Norris, Suzanne, McKiernan, Susan, King, Gerard, Meaney, James F., Daly, Caroline, Byrne, Danielle, Walsh, John P., Murphy, Ross T., McMorrow, Jason, Fagan, Andrew J., Poetrzyk, Aneta Kecler, Durand, Michael E., Norris, Suzanne, McKiernan, Susan, King, Gerard, Meaney, James F., Daly, Caroline

Mayo Clinic

Journal of Thoracic Imaging | April 15, 2022 | Volume: 37 | Issue: 5 | Pages: 300-306

10.1097/rti.0000000000000645 | PMID 35426858 Get It

Background: Iron-overload cardiomyopathy initially manifests with diastolic dysfunction and can progress to dilated cardiomyopathy if untreated. Previous studies have shown that patients with primary and secondary hemochromatosis can have subclinical left ventricle dysfunction with abnormalities on strain imaging. This study aimed to evaluate the relationship between cardiac T2* values and myocardial-wall strain in patients with hereditary hemochromatosis (HH) at the time of diagnosis and after a course of venesection treatment. Materials and Methods: Baseline cardiac magnetic resonance (CMR) at 3 T was performed in 19 patients with newly diagnosed HH with elevated serum ferritin levels and repeated after a course of treatment with venesection. Quantitative T2* mapping and strain analysis were performed offline using dedicated relaxometry fitting and feature-tracking software. Results: The majority (84%) of patients had normal baseline myocardial T2* values (mean 19.3 ms, range 8.9 to 31.2 ms), which improved significantly after venesection (mean 24.1 ms, range 11 to 38.1 ms) (P=0.021). Mean global radial strain significantly improved from 25.0 (range: 15.6 to 32.9) to 28.3 (range: 19.8 to 35.8) (P=0.001) and mean global circumferential strain improved, decreasing from −15.7 (range: −11.1 to −19.2) to −17.1 (range: −13.0 to −20.1) (P=0.001). Conclusion: Patients with HH may have normal T2* values in the presence of subclinical left ventricle dysfunction, which can be detected by abnormal radial and circumferential strain. As strain imaging improves following venesection in HH, it may serve as a useful biomarker to guide treatment.
Efficacy and Safety of Twice-Daily versus Three-Times Daily Saquinavir Soft Gelatin Capsules as Part of Triple Combination Therapy for HIV-1 Infection
Wheat, L. Joseph , Farthing, Charles, Cohen, Calvin, Pierone, Gerald , Lalezari, Jay , Pilson, Robert S, Siemon-Hryczyk, Peggy, Appendix), for the TIDBID (NR15520/M61018) study team (members listed in, Baxter, John, Beer, Victor L., Bellos, Nicholas, Bissett, Jack, Braun, James, Brosgart, Carol, Burnside, Alfred F., Cervia, Joe, Cheeseman, Sarah H., Cimoch, Paul J., Cohen, Calvin, DeJesus, Edwin, Diaz, Leslie L, Dieterich, Douglas T. , Dobkin, Jay F., Dretler, Robin, El-Sadr, Waafa, Eng, Robert H.K., Feleke, Getachew, Fessel, Jeffrey , Fish, Douglas N. , Galpin, Jeffrey E., Gathe, Joseph, Gilson, Ian, Gold, Marla, Goodgame, Jeffrey, Greenberg, Richard N. , Greiger, Paola, Grossman, Howard, Grossman, Ron, Hanna, Barbara, Hathaway, Bruce, Hoffman-Terry, Margaret, Jacobson, Susan , Jemsek, Joseph G., Jordan, Wilbert, Kaplan, Mark, Kostman, Jay R., Landesman, Sheldon H., Lindquist, Craig, Madhava, Valsa, Marsh, Bryan J., Martin, Dean, Mathur‐Wagh, Usha, McMeeking, Alexander, Miao, Peter, Mogyoros, Miguel, Mustafa, Mahmoud M., Nadler, Jeffrey P., Norris, Dorece, Onbirbak, Brian, Parker, Richard H, Pearce, Daniel, Pierone, Gerald, Poblete, Ronald, Poretz, Donald M., Reyelt, M Christine, Rivera-Vazquez, Carlos, Salvato, Patricia, Sands, Michael, Schwartz, Robert A., Sension, Michael, Skowron, Gail, Slater, Leonard N., Stavola, Joseph, Steinhart, Corklin, Temesgen, Zelalem , Thompson, Melanie , Timpone, Joseph, Vollmer, Kelly, Wada, Suzanne, Wheat, L Joseph, Yangco, Bienvenido G., Carey, Peter, Jablonowski, H, Theisen, Albert, Ocana, Inma, Appendix), for the TIDBID (NR15520/M61018) study team (members listed in, Burman, William J. , Cohen, Calvin, Feinberg, Judith , Goodrich, James , Jacobson, Susan, Kaplan, Mark, Lalezari, Jacob , MacArthur, Rodger D. , Murphy, Robert L. , Mustafa, Mahmoud, Pierone, Gerald, Reyelt, M. Christine, Smith, David C. , Valentine, Fred T. , Ward, Douglas, Wheat, L Joseph, Carey, Peter, Lazzarin, Adriano , Ocana, Inma

Mayo Clinic

Antiviral Therapy | April 14, 2022 | Volume: 7 | Issue: 3 | Pages: 199-209

10.1177/135965350200700310 Get It

Objective The objective of this study was to determine whether a triple therapy regimen incorporating twice-daily saquinavir is as effective as a three-times daily regimen. Methods This was an open-label, Phase III, multicentre, 48-week study involving 837 HIV-1-infected patients randomised to one of the following: saquinavir soft gel capsule (SGC) 1200 mg three-times daily, plus two nucleoside reverse transcriptase inhibitors (NRTIs) (arm A); saquinavir SGC 1600 mg twice-daily, plus two NRTIs (arm B); saquinavir SGC 1200 mg twice-daily and nelfinavir 1250 mg twice-daily, plus a single NRTI (arm C). The primary outcome measure was the virological response in arm A versus B and in arm A versus C with respect to the percentage of patients whose plasma HIV-1 RNA levels fell below the level of quantification for the Amplicor assay (<400 copies/ml) at weeks 24 and 48. Results At 48 weeks, the percentage of patients with plasma HIV-1 RNA levels <400 copies/ml was 47.1% (arm A), 45.3% (arm B) and 42.7% (arm C) in the intention-to-treat analysis. The treatment difference between arm B–arm A was -1.8% (95% confidence intervals -10.1, 6.5) and for arm C–arm A was -4.5% (95% confidence intervals -12.7, 3.7) in the intention-to-treat analysis. These differences fell within the maximum allowable difference (±12%) for arm B compared with arm A. At week 24, the percentage of patients with HIV-1 RNA levels <400 copies/ml was 59.6% (arm A), 57.6% (arm B) and 51.3% (arm C). Conclusions A twice-daily triple therapy regimen incorporating saquinavir SGC plus two NRTIs was of equivalent efficacy to the three-times daily regimen studied. All regimens were generally well tolerated.
Rasch‐calibrated Intermittent Exotropia Symptom Questionnaire for Children
Holmes, Jonathan M., Leske, David A., Hercinovic, Amra, Hatt, Sarah R., Chandler, Danielle L., Li, Zhuokai, Melia, B. Michele, Chen, Angela M., Erzurum, Sergul Ayse, Crouch, Eric R., Jenewein, Erin C., Kraker, Raymond T., Cotter, Susan A., Group, Pediatric Eye Disease Investigator, Holmes, Jonathan M. , Holmes, Jonathan M., Leske, David A., Hercinovic, Amra, Hatt, Sarah R., Chandler, Danielle L., Li, Zhuokai, Melia, B. Michele, Chen, Angela M., Erzurum, Sergul Ayse, Crouch, Eric R., Jenewein, Erin C., Kraker, Raymond T., Cotter, Susan A., Group, Pediatric Eye Disease Investigator, Holmes, Jonathan M.

Mayo Clinic

Optometry and Vision Science | April 12, 2022 | Volume: 99 | Issue: 6 | Pages: 513-520

10.1097/opx.0000000000001901 | PMID 35412528 Get It

SIGNIFICANCE A rigorously designed and calibrated symptom questionnaire for childhood intermittent exotropia would be useful for clinical care and for research. PURPOSE The aim of this study was to Rasch‐calibrate and evaluate the previously developed Child Intermittent Exotropia Symptom Questionnaire using data gathered as part of a randomized clinical trial. METHODS The questionnaire was administered to 386 children aged 3 to 10 years with intermittent exotropia who were enrolled in a randomized clinical trial comparing overminus with nonoverminus spectacles. Participants were followed at 6 and 12 months while on treatment and at 18 months off treatment. Factor analysis determined dimensionality, and Rasch analysis evaluated questionnaire performance. Logit values were converted to 0 (best) to 100 (worst). We evaluated differences in questionnaire scores between treatment groups and time points, and correlations with control scores. RESULTS The Child Intermittent Exotropia Symptom Questionnaire was unidimensional. Rasch analysis indicated that there was no notable local dependence and no significant differential item functioning for sex or age. There was suboptimal targeting (mean logit, −1.62), and person separation was somewhat poor (0.95). There were no significant differences in the Child Intermittent Exotropia Symptom score between overminus spectacles and nonoverminus spectacles at 6, 12, and 18 months. Combining data from both treatment groups, there was significant improvement from baseline at all follow‐up visits (e.g., mean change from baseline to 12 months, −6.6 points; 95% confidence interval, −8.6 to −4.6). Child Intermittent Exotropia Symptom scores were not correlated with distance or near control scores at 12 months. CONCLUSIONS The seven‐item Rasch‐scored Child Intermittent Exotropia Symptom Questionnaire is limited by suboptimal performance. Future study is needed to determine whether it may be useful for clinical practice and for research.